What is VivoSense?
Founded in 2010, VivoSense operates at the vanguard of the pharmaceutical clinical trial industry. The company specializes in the development of digital biomarkers, utilizing its proprietary VivoSense software to interpret complex data streams from wearable sensors. By providing rigorous, scientifically-validated analysis of human physiology, the platform enables researchers to derive real-world clinical measures that are essential for precision medicine. The company's solutions are currently deployed across critical therapeutic areas, including oncology, Alzheimer's disease, and various rare conditions, effectively supporting regulatory and medical decision-making processes. Through its commitment to data integrity and scientific foundation, VivoSense is instrumental in advancing the efficacy of drug development pipelines.
How much funding has VivoSense raised?
VivoSense has raised a total of $25.1M across 2 funding rounds:
Debt
$150K
Series A
$25M
Debt (2020): $150K with participation from PPP
Series A (2022): $25M led by Perceptive Xontogeny Venture Fund and Debiopharm
Key Investors in VivoSense
Perceptive Xontogeny Venture Fund
A specialized venture capital firm focused on early-stage life sciences and biotechnology companies, providing both capital and operational expertise.
Debiopharm
The investment division of the Debiopharm Group, focusing on private equity and strategic financial returns to support long-term pharmaceutical innovation.
PPP
Public-Private Partnership
What's next for VivoSense?
Looking ahead, the strategic deployment of this recent capital will likely focus on expanding the company's footprint in global clinical trials and enhancing its suite of analytical tools. As the pharmaceutical industry increasingly pivots toward decentralized trials and real-world evidence, VivoSense is uniquely positioned to capture market share by providing the necessary infrastructure for high-fidelity data interpretation. The company is expected to prioritize the integration of its technology into broader regulatory frameworks, further cementing its role as a standard-bearer for digital clinical measures. By leveraging its recent funding, VivoSense aims to accelerate the delivery of life-saving treatments, ensuring that patient-centric data remains at the heart of modern medical innovation.
See full VivoSense company page
